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Severe vitamin D deficiency is common among Muslim immigrants. The dose necessary to correct the deficiency and its consequence for bone
health are not known for immigrants. The aim was to assess the effect of relatively low dosages of supplemental vitamin D on vitamin D and bone
status in Pakistani immigrants. This 1-year-long randomised double-blinded placebo-controlled intervention with vitamin D3 (10 and 20mg/d)
included girls (10·1–14·7 years), women (18·1–52·7 years) and men (17·9–63·5 years) of Pakistani origin living in Denmark. The main endpoints
were serum 25-hydroxyvitamin D (S-25OHD), parathyroid hormone, bone turnover markers and bone mass. The study showed that supplemen-
tation with 10 and 20mg vitamin D3 per d increased S-25OHD concentrations similarly in vitamin D-deficient Pakistani women (4-fold), and that
10mg increased S-25OHD concentrations 2-fold and 20mg 3-fold in Pakistani men. S-25OHD concentrations increased at 6 months and were
stable thereafter. Baseline S-25OHD concentrations tended to be lower in girls and women than in men; females achieved about 46 nmol/l and
men 55 nmol/l after supplementation. Serum intact parathyroid hormone concentrations decreased at 6 months, but there was no significant
effect of the intervention on bone turnover markers and dual-energy X-ray absorptiometry measurements of the whole body and lumbar spine.
Randomised controlled trials: Vitamin D intervention: Pakistani immigrants: Bone turnover: Bone mass
The large population groups living in a traditional Islamic
cultural pattern in Europe are at major risk of vitamin D
deficiency due to insufficient sun exposure and low vitamin
D intake. Previously, in the cross-sectional part of this
study, we found median 25-hydroxyvitamin D (25OHD)
concentrations between 10·9 and 20·7 nmol/l among adoles-
cent girls, premenopausal women and men with Pakistani
origin living in Denmark(1). Similar results have been reported
in Norway(2 – 5) and in the UK(6).
Clinical trials investigating the effect of vitamin D sup-
plementation on fracture risk have shown conflicting
results(7 – 12). Several of the trials combined Ca with vitamin
D, making it unclear which nutrient is responsible for an
observed effect. However, trials with vitamin D supplemen-
tation alone (dosages 10–20mg/d) also find conflicting
results(10,11,13,14). A meta-analysis of seven randomised trials
found that fracture risk was reduced among ambulatory or
institutionalised elderly individuals at vitamin D supplemental
dosages of 17·5–20mg/d, but not at 10mg/d(15). However, this
differs from a Cochrane review, which found fracture
reduction among elderly institutionalised individuals given
vitamin D and Ca, but the effect of vitamin D alone was
unclear(16). Bone mineral density (BMD) is a useful measure
for predicting fracture risk(17,18), and BMD was increased
with vitamin D and Ca supplementation in some studies
among elderly Caucasians(7 – 9) and with vitamin D sup-
plementation alone in other studies(19 – 21).
Case reports show improvement in vitamin D status (and
reduced muscle pain) by vitamin D supplementation among
immigrants(22,23); however, very few vitamin D intervention
studies have been performed with ethnic groups other than
Caucasians from Western countries. In a small group of vitamin
D-depleted Asians in the UK, treatment with vitamin
D increased their vitamin D status(24). Several surveys
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Abbreviations: BA, bone area; BMC, bone mineral content; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; GLM, general linear model;
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investigated the Asian community in Glasgow during the
1960–80s, and about 10mg vitamin D/d seemed to prevent
rickets and osteomalacia(25 – 29). Vitamin D-fortified chapatti
flour was uniformly effective in increasing 25OHD concen-
trations as vitamin D capsules(25). In a study from Norway
where Pakistani women were advised to take vitamin
D supplements, no improvement in status was shown after 1
year, but whether the advice was followed was not known(3).
A randomised controlled trial of vitamin D supplementation
in Ca-replete African-American women did not observe an
effect on bone loss or bone turnover markers(30).
The purpose of the present study was to assess the effect of
relatively low dosages of supplemental vitamin D on vitamin D
status in an immigrant group where sun exposure and vitamin D
intake is minimal, and to assess the effect of vitamin D sup-
plementation on bone turnover and bone mass in this group.
The main endpoints were serum 25-OHD (S-25OHD), serum
intact parathyroid hormone (S-iPTH), and markers for bone
turnover and bone mass. The relatively low dosages (the
recommended daily intake and twice the recommended daily
intake for this population group) used in the present study
were chosen with a view to the possibility of fortification.
Subjects and methods
Study design
The study was a 1-year-long randomised double-blinded pla-
cebo-controlled intervention study with two doses of vitamin
D3 (10 and 20mg/d). The subjects were seen three times
during the year, at months 0, 6 and 12. The main endpoints
were S-25OHD, S-iPTH, bone turnover markers and markers
of bone mass (whole-body and lumbar spine bone area
(BA), BMD and bone mineral content (BMC)).
The local ethics committee (registration no. KA01139gs)
and the Danish Medicines Agency (a tablet containing 20mg
vitamin D3 is considered as a drug and not a supplement in
Denmark) (registration no. 2612-1805) approved the study
protocol. The study was carried out in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from all participants, as well as from the parents or
guardians of the girls.
Subjects
Subjects were recruited through information meetings at
schools, mosques, cricket clubs, private organisations, etc,
adverts in local Pakistani newspapers, local Pakistani radio
and television, and posters in relevant places, since the
Danish National Central Offices of Civil Registrations do
not contain information about ethnic origin. Consequently,
the sample was not random and the representativeness of the
sample could not be assessed due to lack of information
about non-acceptors. The subjects were included from January
2002 to November 2002.
Subjects included were adolescent girls (median age 12·2
years; range 10·1–14·7 years), women (median age 36·2 years;
range 18·1–52·7 years) and men (median age 38·3 years;
range 17·9–63·5 years). All subjects were of Pakistani
origin (immigrants or descendants with Pakistani parents)
primarily living in the Copenhagen area, Denmark (latitude
558N). About 87 % of the 19 250 individuals with Pakistani
origin (immigrants and descendants) in Denmark live in the
Copenhagen area(31). The baseline S-25OHD status and the
determinants of vitamin D status (for example, clothing, sun
and smoking habits) were investigated earlier(1).
Among the 247 subjects participating in the first visit, 199
(twenty-six girls, eighty-nine women and eighty-four men)
were willing to be included in the intervention study (month
0). Twenty-two girls, sixty-five women and sixty-nine men
participated in the second visit at month 6. Twenty-one
girls, sixty-two women and sixty-five men were seen at
month 12, and thus completed the study (the overall drop-
out rate at the end of the study was 26 %, and 19, 30 and
23 % for girls, women and men, respectively).
The goal was to recruit sixty girls, sixty women, and sixty
men, i.e. twenty girls, twenty women and twenty men in
each of the three treatment groups (this number would be
able to detect a change in BMD of the same size as the popu-
lation standard deviation, 0·025 g/cm2, i.e. a change of 1 SD
(provided significance level 5 %, power 85 %)).
Exclusion criteria were medications known to affect bone
metabolism or S-25OHD concentrations (anti-epileptics,
active vitamin D metabolites, corticosteroids, thyroid hor-
mones, bisphosphonates, oestrogens), serious illness (for
example, cancer, or liver or kidney insufficiency), pregnancy,
planning pregnancy within 1 year, breast-feeding, and serum
ionised Ca concentrations .1·5 mmol/l.
The women were tested for pregnancy before dual-energy
X-ray absorptiometry (DXA) scanning. Subjects with incom-
plete data in one or more of the explanatory variables were
excluded in the multiple regression analyses, and they did
not differ significantly from the study population with respect
to S-25OHD and the available explanatory variables.
Tablets
Scanpharm A/S (Birkerød, Denmark) produced the placebo
(cellulosum microcristallium) and vitamin D3 (10 and 20mg)
tablets especially for the present study without using any
pig-containing substances. Scanpharm A/S delivered the
three kinds of tablets in coded boxes. The subjects (girls,
women and men separately) were randomised (by an impartial
scientist) in blocks of six using random numbers.
At the first visit, 3 months’ consumption of tablets were
handed out, the next 3 months’ consumption were sent by
mail to the subjects, and at the second visit the remaining 6
months’ consumption of tablets were handed out. The subjects
were instructed to bring back any remaining tablets at
the second and third visit, and the compliance was calculated
by tablet counting. The median compliance was 85 (range
43–100), 92 (42–115) and 93 (33–105) % for girls, women
and men, respectively.
Sampling and analyses of biochemical parameters
Blood samples were taken between 07.30 and 10.30 hours at all
three visits (months 0, 6 and 12) by venepuncture after an over-
night fast. Local anaesthetic patches were offered to the girls to
reduce the discomfort of venepuncture. Blood samples were
centrifuged (about 3000 g for 10 min) within 2 h of sampling,
and serum was frozen and stored at 2808C. Morning second
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void urine samples were collected after an overnight fast. Urine
samples were frozen and stored at 2208C.
S-25OHD concentrations (vitamin D2 plus D3 are used
here) were analysed by HPLC using a diode array detector
for detection and an absorbance detector for quantification.
The inter-assay CV was 6·3 % and the intra-assay CV was
4·3 %. S-25OHD was analysed at the National Food Institute,
Denmark. Participation in the Vitamin D External Quality
Assessment Scheme (Charing Cross Hospital, London, UK)
ensured that the HPLC method was in agreement with com-
mercially available assays.
S-iPTH concentrations were analysed by an immunoradio-
metric method using a commercial assay (IDS, Bolton,
Lancs, UK). The inter-assay CV was 4·0 % and the intra-
assay CV was 2·3 %. Urinary Ca was analysed by an absorp-
tiometry method using a KoneLab spectrophotometer (Thermo
Clinical Labsystems Ltd, Espoo, Finland). The inter- and
intra-assay CV were less than 5 %. S-iPTH and urinary Ca
were analysed at the University of Helsinki, Finland.
Serum osteocalcin was analysed by an ELISA (BRI-Diag-
nostics, Dublin, Republic of Ireland). The inter-assay CV
was 11 % and the intra-assay CV was 8 %.
Urinary pyridinoline and deoxypyridinoline were measured
by HPLC with fluorescence detection and quantified by external
standardisation using a commercially available pyridinoline/
deoxypyridinoline HPLC calibrator (Metra Biosystems Ltd,
Wheatley, Oxon, UK). The inter-assay CV was 9 and 11 %,
respectively and the intra-assay CV was 6 and 7 %, respectively.
Urinary creatinine was analysed by a colorimetric procedure
using a diagnostic kit (catalogue no. 124; Boehringer Man-
nheim GmbH, Mannheim, Germany). The inter-assay CV
was 6·7 % and the intra-assay CV was 3·2 %.
Serum osteocalcin, urinary pyridinoline and urinary deoxy-
pyridinoline were analysed at University College Cork
(Republic of Ireland).
Serum ionised Ca was analysed by a Caþþ /pH Analyser
Ciba Corning 634 with ion-selective electrodes. The inter-assay
CV was 2·4 % on level 1·23 mmol/l and the intra-assay CV was
0·8 % on level 1·16 mmol/l (external quality control: DEKS
(Danish Institute for External Quality Assurance for Laboratories
in Health Care)). Ionised Ca was analysed at the Department
of Clinical Biochemistry (Hvidovre Hospital, University of
Copenhagen, Denmark). Serum ionised Ca and urine Ca
were measured to check for developing hypercalcaemia.
Bone mineral assessment
At the first and third visit (months 0 and 12) whole-body and
lumbar (L2–L4) BMC measured in g hydroxyapatite, bone
size expressed as anterior–posterior projected BA measured
in cm2, and BMD measured in g/cm2 (BMD ¼ BMC/BA)
were determined by DXA scan using a Hologic 1000/W scan-
ner (Hologic, Inc., Waltham, MA, USA). The method is
described elsewhere(1).
Dietary intake and background information
At the first and third visit (months 0 and 12) the subjects
answered an FFQ that ascertained the food groups contributing
to 95 % of the vitamin D intake and 75 % of the Ca intake
determined from the Danish national dietary survey, which,
however, does not contain intake data from Pakistani immi-
grants(32). The intake calculations were performed using the
General Intake Estimation System described elsewhere(33,34).
At the first visit (month 0) the subjects answered a detailed
questionnaire that ascertained demographic characteristics,
chronic diseases, use of medication and other lifestyle vari-
ables. At the second and third visit (months 6 and 12) the sub-
jects answered a questionnaire ascertaining changes in disease
or use of medication. Weight and height were recorded with-
out shoes at all three visits. The age of the subjects at months
0 and 12 was the age on the date of blood sampling and inter-
view. The median age difference between month 12 and 0 is
1·04 (range 0·99–1·12), 1·05 (range 0·92–1·32) and 1·05
(range 0·92–1·25) years for girls, women and men, respect-
ively (drop-outs excluded).
Statistical analysis
All statistical analyses were performed for girls, women and
men separately. Analyses included standard descriptive stat-
istics. The significance level was chosen as 0·05. SAS version
8.02 (SAS Institute, Inc., Cary, NC, USA) was used for all
statistical analyses.
Non-parametric ANOVA was performed in order to compare
the three treatment groups at baseline (month 0) in age, anthro-
pometrics, vitamin D dietary intake, Ca dietary intake, bio-
chemical markers and bone mass. Non-parametric ANOVA
was also performed in order to compare the three treatment
groups at the end of the study (month 12) in age, anthropo-
metrics, vitamin D dietary intake and Ca dietary intake.
Age- and baseline-corrected multiple regression (general
linear model; GLM) was performed in order to quantify the
effect of tablet dose (0, 10 or 20mg vitamin D3/d) on various out-
comes at endpoint (12 month) as an intention-to-treat analysis.
Outcomes were biochemical markers and markers for bone
mass, all logarithmically transformed in order to meet the
requirements of the statistical model. Likewise, the correspond-
ing baseline measurements (month 0) were also logarithmically
transformed, whereas age was included as a quantitative covari-
ate without transformation. Pair-wise comparisons between the
three dose groups were performed using Tukey adjustment, and
effects are stated as estimated ratios between a high-dose indi-
vidual compared with a low-dose individual.
In order to investigate further the dose–time interaction, we
included all three time points in a repeated-measurement
analysis (mixed linear model; MIXED), including subject as
a random factor (compound symmetry correlation structure).
Age was included as a quantitative covariate, dose and time
as fixed factors, the latter described by two dummy variables
indicating successive time differences.
A direct comparison of the effect over 12 months (for all vari-
ables) for dose 20mg/d as compared with placebo was calculated
for subjects completing the study. The effect is expressed as the
ratio of change in the respective groups, so that, for example, a
ratio of 2 indicates that dose 20mg/d causes the variable to
increase with twice the rate as compared with placebo.
Results
The baseline subject characteristics of the three treatment
groups are shown in Table 1. There were no significant
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differences (P.0·05; non-parametric ANOVA) between the
three treatment groups in subject characteristics either at
baseline (month 0) (Table 1) or at the end of the study
(month 12) (data not shown). There was also no significant
difference between the three treatment groups at baseline in
S-25OHD, S-iPTH, serum osteocalcin, urinary pyridinoline
and urinary deoxypyridinoline for girls, women and men
(Tables 2 and 3). Serum ionised Ca and urinary Ca were
measured at all three visits. No subjects developed hypercal-
caemia (serum ionised Ca was below 1·5 mmol/l for all sub-
jects at all visits). There was no significant difference
(P.0·05; non-parametric ANOVA) between the three
treatment groups in serum and urinary Ca either at baseline
(month 0) or at the end of the study (month 12) (data
not shown).
Serum 25-hydroxyvitamin D
There was a significant difference (Table 2; GLM) between
the three treatment groups at end of the study (month 12)
in S-25OHD for girls, women and men. Vitamin D sup-
plementation elevated median S-25OHD concentrations in
all groups; for women concentration increased by 31–
32 nmol/l with both 10 and 20mg/d, and for the men
S-25OHD increased 16·5 nmol/l with 10mg/d and 35·8 nmol/
l with 20mg/d (the baseline and final values are shown in
Table 2). Vitamin D status of the women increased about
four times by intake of both 10 and 20mg/d; for men vitamin
D status increased about two times by intake of 10mg/d and
about three times by 20mg/d (Table 2; GLM). S-25OHD con-
centration increased significantly between months 0 and 6, and
did not increase further from months 6 to 12 (Table 2;
MIXED). However, there were individuals with increased
S-25OHD during months 6 to 12, as seen in Fig. 1, which
shows the S-25OHD raw data and illustrates the entire course
of the intervention.
Figure 2 shows the relationship between the outcome and
baseline S-25OHD concentrations (logarithmically trans-
formed) for women and men (not shown for girls due to the
low number of subjects). As seen in Fig. 2, the outcome concen-
trations depend on baseline values both for intake of 10 and
20mg/d for women, and the slope is similar for both treatment
groups (a ¼ 0·3 and 0·2 for doses 10 and 20mg/d, respectively).
For men the endpoint concentrations depend on baseline values
only for intake of 10mg/d (a ¼ 0·3), whereas for the 20mg/d
treatment group the slope was close to zero (a ¼ 20·004) and
thus independent of the baseline value. This illustrates an
interaction between dose and baseline value, which is confirmed
by including this interaction term in the GLM analysis; the
interaction is significant for men (P¼0·0045), but not for
women.
Serum intact parathyroid hormone
Vitamin D supplementation decreased S-iPTH significantly
between months 0 and 6 for girls, women and men, but not
between months 6 and 12 (Table 2; MIXED). There was a sig-
nificant difference between the three treatment groups at the
end of the study (month 12) for women, but not for girls
and men (Table 2; GLM). There was no significant difference
in S-iPTH between dose 10 and 20mg/d for girls, women and
men (data not shown).
Bone turnover (serum osteocalcin, urinary pyridinoline and
urinary deoxypyridinoline)
There was no significant difference (GLM) between the three
treatment groups at the end of the study (month 12) and there
Table 1. Subject characteristics of vitamin D3-supplemented and placebo groups at month 0 (baseline)*†
(Medians with 25th and 75th percentiles)
Group. . . Placebo 10mg 20mg
Median 25th, 75th percentiles Median 25th, 75th percentiles Median 25th, 75th percentiles
Girls (n) 8 9 9
Age (years) 12·6 11·3, 13·8 12·8 11·4, 13·6 11·9 11·1, 12·4
Weight (kg) 50·5 43·2, 52·9 43·4 36·3, 54·6 49·1 40·0, 57·9
Height (cm) 153·7 148·5, 160·6 151·0 147·1, 157·9 151·5 150·5, 158·2
BMI (kg/m2) 21·2 17·4, 22·4 16·5 16·2, 22·7 21·0 18·7, 23·5
Dietary vitamin D intake (mg/d) 2·0 1·3, 2·4 1·9 1·2, 2·0 1·6 1·4, 2·2
Dietary Ca intake (mg/d) 510 309, 1017 557 444, 997 656 460, 1281
Women (n) 29 30 30
Age (years) 36·1 25·3, 47·2 33·4 22·9, 43·9 36·3 30·6, 44·1
Weight (kg) 68·4 57·1, 72·3 67·1 58·1, 75·8 68·2 56·9, 78·2
Height (cm) 156·4 153·3, 161·9 159·1 155·3, 161·1 156·7 153·0, 160·7
BMI (kg/m2) 27·1 22·5, 30·5 26·7 24·2, 30·3 27·3 22·6, 32·0
Dietary vitamin D intake (mg/d) 1·5 1·0, 2·5 1·7 1·3, 2·3 1·8 1·2, 2·8
Dietary Ca intake (mg/d) 495 350, 679 533 413, 638 459 299, 794
Men (n) 27 26 31
Age (years) 40·8 31·5, 51·1 36·6 32·5, 50·6 39·1 31·4, 51·5
Weight (kg) 77·2 71·2, 89·0 81·7 74·0, 92·6 77·4 67·9, 83·0
Height (cm) 170·7 167·7, 175·2 174·5 169·8, 177·9 168·3 165·1, 176·7
BMI (kg/m2) 27·0 25·3, 30·6 27·6 25·2, 28·2 25·8 23·7, 29·9
Dietary vitamin D intake (mg/d) 2·1 1·5, 3·5 1·8 1·6, 3·3 2·4 1·7, 4·9
Dietary Ca intake (mg/d) 548 428, 780 541 472, 772 581 481, 765
*No significant difference between treatment groups at baseline (P.0·05; non-parametric ANOVA).
†Baseline characteristics of drop-outs were not significantly different from those completing the study (P.0·05; non-parametric ANOVA).
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Table 2. Serum 25-hydroxy vitamin D (S-25OHD) and serum intact parathyroid hormone (S-iPTH) in the three treatment groups at month 0, 6 and 12, and P values from the two statistical tests
performed (general linear model (GLM) and mixed linear model (MIXED))
(Medians with 25th and 75th percentiles)
Girls Women Men
S-25OHD (nmol/l) S-iPTH (pmol/l) S-25OHD (nmol/l) S-iPTH (pmol/l) S-25OHD (nmol/l) S-iPTH (pmol/l)
Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles
Placebo
Subjects month 0 (n) 8 29 27
Subjects month 6 (n) 7 20 22
Subjects month 12 (n) 7 19 20
Month 0* 7·30 5·30, 23·6 3·97 3·58, 5·74 11·7 7·5, 19·4 4·02 2·99, 5·12 20·0 15·0, 25·2 3·50 2·71, 4·04
Month 6 7·97 5·33, 18·5 4·92 2·69, 8·29 5·72 4·96, 10·5 4·47† 3·78, 5·55 12·1 7·90, 18·8 3·35 2·95, 4·08
Month 12 5·75 4·88, 16·0 4·03‡ 3·22, 5·34 10·1 8·38, 16·1 3·92 2·82, 4·80 19·1 13·1, 22·6 3·30 2·65, 3·71
10mg/d
Subjects month 0 (n) 9 30 26
Subjects month 6 (n) 7 22 20
Subjects month 12 (n) 7 21 19
Month 0* 16·9 12·1, 21·1 3·53 2·74, 4·94 9·95 6·90, 14·3 3·46 2·90, 4·20 22·9 12·6, 28·2 3·14 2·77, 4·13
Month 6 45·7 30·4, 54·3 2·87 1·73, 3·81 43·4 38·7, 49·4 2·96 2·63, 4·11 37·8 27·1, 45·5 2·70† 2·38, 3·30
Month 12 47·0 28·7, 61·5 2·75 1·55, 3·38 40·9 37·4, 47·7 2·62 2·14, 2·94 39·4 31·0, 48·2 2·76§ 2·13, 3·80
20mg/d
Subjects month 0 (n) 9 30 31
Subjects month 6 (n) 8 23 27
Subjects month 12 (n) 7 22 26
Month 0* 8·80 5·20, 17·1 4·29 2·90, 5·61 14·0 8·30, 17·5 3·69 2·78, 4·61 18·9 13·6, 29·2 3·44 2·72, 4·27
Month 6 51·1 31·8, 57·9 2·56 1·66, 3·67 46·4 30·1, 53·4 3·11k 2·80, 2·88 53·6 47·0, 62·8 2·63 2·22, 3·63
Month 12 29·3 28·5, 64·0 2·90 1·15, 3·56 46·2 38·6, 53·2 3·06 2·33, 3·62 54·7 45·2, 65·1 3·04 2·54, 4·35
Ratio of change (CI){ 3·61 1·54, 8·45 0·62 0·36, 1·07 4·94 3·93, 6·22 0·89 0·69, 1·15 3·27 2·33, 4·58 0·98 0·77, 1·24
P value (ratio**)
GLM
Dose 0–10 0·03 (3·48) NS ,0·0001 (4·04) 0·001 (0·68) ,0·0001 (2·10) NS
Dose 0–20 NS NS ,0·0001 (4·19) NS ,0·0001 (3·09) NS
Dose 10–20 NS NS NS NS 0·006 NS
MIXED
Month 0–6 0·004 0·02 ,0·0001 0·0007 ,0·0001 0·03
Month 6–12 NS NS NS NS NS NS
NS, non-significant (P.0·05).
* No significant difference between treatment groups at baseline (month 0) (P.0·05; non-parametric ANOVA).
† n 19.
‡ n 6.
§ n 18.
kn 22.
{Ratio of change (CI) over 12 months for dose 20mg/d as compared with placebo for subjects completing the study.
** Effects are stated as estimated ratios between a high-dose individual compared with a low-dose individual.
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Table 3. Serum osteocalcin (S-Osteo), urine pyridinoline (U-Pyr) and urine deoxypyrodinoline (U-dPyr) in the three treatment groups at months 0, 6 and 12
(Medians with 25th and 75th percentiles)
Girls Women Men
S-Osteo (ng/ml)
U-Pyr (nmol/mmol
creatinine)
U-dPyr (nmol/mmol
creatinine) S-Osteo (ng/ml)
U-Pyr (nmol/mmol
creatinine)
U-dPyr (nmol/mmol
creatinine) S-Osteo (ng/ml)
U-Pyr (nmol/mmol
creatinine)
U-dPyr (nmol/mmol
creatinine)
Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles
Placebo†
Subjects
month 0 (n)
8 29 27
Subjects
month 6 (n)
7 20 22
Subjects
month 12
(n)
7 19 20
Month 0* 37·3 27·8, 41·7 37·9‡ 20·7, 45·6 20·3‡ 17·2, 25·8 7·88 6·22, 10·5 9·51§ 7·56, 14·3 4·93§ 4·24, 6·45 10·1 7·65, 12·7 11·4§ 7·67, 18·0 6·53§ 3·76, 8·78
Month 6 32·6 15·4, 49·0 32·9k 16·3, 50·8 23·2k 14·4, 28·2 7·88 6·84, 9·70 8·70{ 7·28, 13·4 4·44{ 4·09, 6·45 9·45 8·10, 12·3 9·89 6·75, 14·0 6·41 2·87, 7·71
Month 12 24·7 20·1, 29·0 33·2 21·6, 54·2 28·8 15·2, 33·6 8·27 6·27, 9·93 14·2** 9·83, 16·4 6·29** 5·32, 7·96 9·24 6·95, 11·3 10·1{ 8·87, 14·8 5·33{ 4·63, 6·38
10mg/d†
Subjects
month 0 (n)
9 30 26
Subjects
month 6 (n)
7 22 20
Subjects
month 12
(n)
7 21 19
Month 0* 38·4 21·3, 9·2 32·2 21·1, 41·3 38·5 22·2, 3·0 7·92 6·52, 11·5 9·33†† 7·31, 14·2 5·24†† 3·72, 7·79 8·27 7·18, 12·2 11·2§ 8·79, 19·0 6·88§ 3·75, 10·7
Month 6 39·5 17·4, 0·8 40·5‡ 23·4, 124·2 26·1‡ 25·1, 6·6 8·03 6·68, 10·5 9·85‡‡ 8·01, 16·9 4·32‡‡ 3·40, 7·62 8·65 7·62, 11·9 11·4 7·71, 13·8 4·94 3·20, 7·78
Month 12 39·4 16·2, 4·1 27·1‡ 19·6, 37·4 23·8‡ 12·0, 4·7 7·97 6·77, 10·7 11·8{ 7·22, 20·4 5·20{ 3·11, 8·77 8·99 7·24, 11·2 12·6 7·06, 16·3 4·25 3·14, 7·20
20mg/d†
Subjects
month 0 (n)
9 30 31
Subjects
month 6 (n)
8 23 27
Subjects
month 12
(n)
7 22 26
Month 0* 58·8 52·6, 3·5 36·5 20·4, 4·6, 9 22·3 12·9, 2·7 7·31 6·19, 9·47 9·84§§ 6·86, 16·8 5·38§§ 3·83, 9·15 9·79 8·44, 12·8 12·3kk 8·54, 26·4 5·12kk 3·34, 8·70
Month 6 45·7 34·9, 0·2 41·8 27·5, 50·3 23·9 14·6, 6·0 7·44 6·16, 9·18 8·88{{ 7·46, 14·4 4·81{{ 3·57, 6·84 11·0 8·36, 12·9 10·6*** 7·64, 18·0 4·91*** 3·89, 6·40
Month 12 33·3 18·8, 9·6 68·3‡ 57·6, 85·7 27·8‡ 22·5, 6·9 7·00 6·28, 8·15 14·2‡‡ 8·81, 19·7 5·72‡‡ 5·12, 8·54 9·16 8·38, 13·7 13·0§ 9·57, 15·6 4·95§ 3·87, 6·33
Ratio of
change
(CI)†††
0·77 0·48, 1·23 1·55 0·80, 3·01 1·14 0·48, 2·72 0·94 0·78, 1·12 0·91 0·62, 1·33 0·95 0·65, 1·39 1·08 0·92, 1·26 0·88 0·56, 1·38 1·04 0·65, 1·65
* No significant difference between treatment groups at baseline (month 0) (P.0·05; non-parametric ANOVA).
† No significant difference between treatment groups (P.0·05; general linear model and mixed linear model).
‡ n 6.
§ n 25.
k n 5.
{ n 19.
** n 18.
†† n 29.
‡‡ n 21.
§§ n 27.
kkn 30.
{{n 23.
*** n 24.
††† Ratio of change (CI) over 12 months for dose 20mg/d as compared with placebo for subjects completing the study.
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was no significant dose–time interaction for any of the bone
turnover markers for girls, women and men (MIXED)
(Table 3). Based on the confidence limits (Table 3), we
cannot rule out the possibility of a clinically relevant effect;
an effect might have been found if we had studied more
subjects.
Bone mass (whole-body and lumbar spine bone mineral
content, bone area and bone mineral density)
There was no significant difference (non-parametric ANOVA)
between the three treatment groups at baseline in whole-body
and lumbar spine BMC, BA and BMD for women and girls
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G
ir
ls
W
o
m
en
M
en
90
80
70
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
S
-2
5O
H
D
 (
n
m
o
l/l
)
Month
0 6 12 0 6 12 0 6 12
0 6 12 0 6 12 0 6 12
0 6 12 0 6 12 0 6 12
Fig. 1. The effect of vitamin D supplementation on serum 25-hydroxyvitamin D (S-25OHD) concentrations (nmol/l) for each subject (girls, women and men separ-
ately) in each treatment group (placebo, 10mg vitamin D3/d and 20mg vitamin D3/d) at visit 1 (month 0, baseline), visit 2 (month 6) and visit 3 (month 12, outcome).
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Fig. 2. The relationship between endpoint and baseline serum 25-hydroxyvitamin D (S-25OHD) (logarithmically transformed) for each subject (women (A) and
men (B) separately) in each treatment group (placebo (K), 10mg vitamin D3/d (W) and 20mg vitamin D3/d (X)).
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Table 4. Whole-body and lumbar spine bone mineral content (BMC), bone area (BA) and bone mineral density (BMD) in the three treatment groups at months 0 and 12
(Medians with 25th and 75th percentiles)
Girls Women Men
BMC (g) BA (cm2) BMD (g/cm2) BMC (g) BA (cm2) BMD (g/cm2) BMC (g) BA (cm2) BMD (g/cm2)
Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles Median
25th, 75th
percentiles
Placebo‡
Whole body
Month 0 (n) 8 28 26
Month 12 (n) 7 19 18
Month 0* 1666 1399, 1767 1760 1561, 1822 0·95 0·88, 0·98 2241 1983, 2469 2055 1833, 2126 1·11 1·05, 1·15 2637 2390, 2912 2281 2111, 2358 1·16 1·08, 1·23
Month 12 1923 1730, 2145 1906 1770, 2123 1·01 0·97, 1·03 2302 2098, 2541 2043 1932, 2176 1·13 1·09, 1·20 2778 2420, 2873 2299 2160, 2390 1·19 1·14, 1·24
Lumbar spine
Month 0 (n) 8 29 27
Month 12 (n) 7 18 19
Month 0* 33·9 26·1, 42·4 43·2 38·4, 47·0 0·78 0·66, 0·92 49·0 45·0, 59·9 50·1 48·1, 55·3 0·99 0·91, 1·12 63·0 53·3, 69·8 61·3 57·6, 64·1 1·03 0·96, 1·14
Month 12 41·9 38·9, 48·2 46·5 44·7, 50·3 0·91 0·84, 0·95 50·1 45·6, 60·7 50·6 47·4, 53·9 1·00 0·89, 1·16 66·9 59·1, 74·3 60·9 58·3, 64·4 1·06 0·90, 1·14
10mg/d‡
Whole body
Month 0 (n) 9 29 23
Month 12 (n) 7 21 18
Month 0* 1308 1104, 1726 1497 1339, 1725 0·87 0·82, 0·99 2222 2043, 2512 2032 1858, 2197 1·10 1·04, 1·17 2684 2406, 2779 2325 2168, 2398 1·14 1·09, 1·20
Month 12 1595 1302, 1953 1669 1534, 1872 0·96 0·85, 1·04 2172 1947, 2536 2007 1841, 2148 1·11 1·04, 1·18 2703 2474, 2869 2334 2168, 2438 1·16 1·11, 1·18
Lumbar spine
Month 0 (n) 9 30 25
Month 12 (n) 7 21 19
Month 0* 28·3 24·7, 35·8 41·2 35·6, 45·9 0·72 0·65, 0·83 54·7 49·9, 62·2 51·9 48·0, 56·3 1·06 0·99, 1·06 66·5 58·5, 71·7 64·1 59·3, 67·5 1·03 0·94, 1·07
Month 12 35·6 30·9, 47·4 42·7 38·8, 48·9 0·82 0·78, 0·96 55·5 49·4, 59·8 51·6 48·3, 55·0 1·06 1·01, 1·11 68·2 60·4, 72·9 64·6 61·8, 68·4 1·05 0·97, 1·11
20mg/d‡
Whole body
Month 0 (n) 9 30 28
Month 12 (n) 7 22 23
Month 0*† 1473 1209, 1887 1633 1441, 1973 0·88 0·84, 0·93 2208 1997, 2370 2001 1891, 2109 1·09 1·06, 1·14 2418 2144, 2635 2101 1986, 2278 1·11 1·08, 1·20
Month 12 1625 1380, 2140 1784 1569, 2026 0·91 0·88, 1·05 2221 2012, 2291 2032 1888, 2093 1·08 1·05, 1·11 2437 2104, 2644 2116 1929, 2285 1·10 1·08, 1·21
Lumbar spine
Month 0 (n) 9 30 31
Month 12 (n) 7 21 26
Month 0*† 30·0 25·4, 32·5 39·9 37·9, 42·2 0·73 0·67, 0·75 50·6 46·1, 55·8 50·5 48·1, 55·1 0·98 0·93, 1·05 55·6 49·0, 64·8 58·3 54·8, 62·9 0·92 0·89, 1·08
Month 12 39·5 27·6, 41·9 42·7 38·7, 46·0 0·88 0·73, 0·95 50·4 46·7, 55·4 50·0 48·5, 53·1 0·99 0·93, 1·08 56·3 50·9, 67·8 57·2 55·2, 62·3 1·00 0·88, 1·12
Ratio of change
(CI) whole
body§
1·04 0·96, 1·13 1·03 0·97, 1·09 1·02 0·98, 1·05 1·01 0·996, 1·02 1·02 1·005, 1·03 0·99 0·98, 0·999 1·01 1·005, 1·02 1·01 0·998, 1·02 1·01 0·999, 1·01
Ratio of change
(CI) lumbar
spine§
1·08 0·95, 1·23 1·02 0·96, 1·07 1·07 0·99, 1·16 1·01 0·98, 1·03 1·00 0·98, 1·01 1·01 0·996, 1·02 1·02 0·999, 1·05 1·01 0·998, 1·02 1·02 0·997, 1·04
* No significant difference between treatment groups at baseline (month 0) (P.0·05; non-parametric ANOVA).
† Significant difference between treatment groups at baseline for men: whole-body BMC P¼0·04 and BA P¼0·007; lumbar spine BMC P¼0·02 and BA P¼0·009 (non-parametric ANOVA).
‡ No significant difference between treatment groups (P.0·05; GLM). For the exceptions (whole-body BMC for men, BMD and BA for women), please refer to the text.
§ Ratio of change (CI) over 12 months for dose 20mg/d as compared with placebo for subjects completing the study.
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(Table 4). There were, however, significant differences
between the three treatment groups at baseline for men in
whole-body and lumbar spine BMC and BA (Table 4).
There was no significant difference (GLM) between the three
treatment groups at the end of the study (month 12) in BMC, BA
and BMD (whole body and lumbar spine) for girls. For men there
was a significant increase in whole-body BMC (P¼0·049;
ratio ¼ 1·01) by supplementation with 20mg/d. For women
there was a significant increase in whole-body BA (P¼0·02;
ratio ¼ 1·02) and significant decrease in whole-body BMD
(P¼0·02; ratio ¼ 0·99) by supplementation with 20mg/d. The
different directions of the estimated ratios weaken these findings
for women. There was no significant difference in any of the
lumbar spine bone parameters for women and men. The confi-
dence limits (Table 4) did not indicate clinical relevant effects
on bone mass.
Discussion
The present study showed that supplementation with 10 and
20mg vitamin D3 per d increased S-25OHD concentrations
similarly in vitamin D-deficient Pakistani women (4-fold),
and that 10mg increased S-25OHD concentrations 2-fold
and 20mg 3-fold in Pakistani men. S-25OHD concentrations
increased at 6 months and were stable thereafter. Baseline
S-25OHD concentrations tended to be lower in girls and
women than in men; females achieved about 46 nmol/l and
men 55 nmol/l after supplementation. S-iPTH concentrations
decreased at 6 months, and there was no significant difference
in S-iPTH between the 10 and 20mg/d treatment groups.
The other main finding of the present study was the lack of
significant effect of the vitamin D intervention on bone turn-
over markers and on markers of bone mass (BMC, BMD, BA).
For girls, the lack of significant effects could be due to lack
of statistical power, since fewer than the scheduled sixty
subjects were recruited. For women, the different directions
of the estimated ratios (0·99 and 1·02) weaken the significant
differences found (whole-body BMD and BA), and for men,
the only significant P value (whole-body BMC; 0·049) was
close to 0·05, and it cannot be concluded that vitamin D sup-
plementations had an effect on bone mass. One could discuss
whether the S-25OHD values are high enough to affect the
bone parameters; the S-25OHD concentrations did not reach
70–80 nmol/l, which is often considered the optimal concen-
tration for bone health(35), at least among elderly Caucasians.
However, in the present study there was no significant diffe-
rence in S-iPTH between the 10 and 20mg/d treatment
groups. Further studies in different ethnic population groups
are needed to clarify whether doses above 20mg/d and study
durations longer than 1 year would increase S-25OHD and
decrease S-iPTH further and thereby improve bone health.
The non-random recruitment of the sample is a limitation of
the present study. The drop-out rate was high; however, we
expected this problem and mitigated it by recruiting more sub-
jects to start with (except for the girls, since parents were not
very willing to let their daughters participate). The compliance
was calculated by tablet counting, but we could obviously not
control the actual tablet intake. It was not within the scope of
this project to measure muscle strength; however, it could
have been interesting to do so. We did ask questions about
muscle pain (duration and degree). However, the questions
were compounded by language difficulties; consequently the
questions were not included in the analyses. In the discussion
of optimal vitamin D status one must keep in mind the diffi-
culties in comparing S-25OHD concentrations in different
studies due to large inter-laboratory variations(36 – 38).
The clinical trials evaluating the effect of vitamin D sup-
plementation on bone mass and/or fracture risk are mainly per-
formed among Caucasians elderly women, some even frail or
institutionalised(7,11), and the trials have produced conflicting
results(7–12). The specific benefit to be gained from increasing
vitamin D intake remains to be defined for other ethnic groups.
It has been suggested that vitamin D supplementation is likely
to have favourable effects on the skeleton among black sub-
jects(39); however, a 3-year randomised controlled trial of vitamin
D supplementation (20–50mg/d) in Ca-replete postmenopausal
African-American women did not find an effect on bone loss
or bone turnover markers(30). Whether the lack of effect on
bone turnover and bone density is due to ethnic differences or
other reasons, we do not know. Studies from Norway found simi-
lar BMD and bone turnover markers among Pakistanis and Nor-
wegians in spite of different S-25OHD(40,41).
Even though we did not find a beneficial effect of vitamin D
supplementation on bone parameters, the improved vitamin D
status among immigrants might affect muscle strength and the
risk of other diseases beneficially. Hypovitaminosis D myopa-
thy is a prominent symptom of vitamin D deficiency, and
severely impaired muscle function may be present even
before biochemical signs of bone disease develop(22). Besides,
vitamin D deficiency may increase the risk of several other
diseases, for example, autoimmune diseases, some types of
cancers, and diabetes(42).
Convincing immigrants to consume supplemental vitamin D
every day for a longer period of time would certainly represent
a major challenge. Food fortification could be a more realistic
solution. The relatively low dosages used in the present study
were chosen with a view to the possibility of fortification. Pre-
sently in Denmark margarine can voluntarily be fortified with
7·5–10mg vitamin D per 100 g. Fortification of chapatti flour,
which could be a way to reach Pakistani immigrants, was
tested in the 1970s in the UK, but it was not recommended,
since the age consumption pattern was not favourable to the
aims of fortification and not all Asians eat chapatti(24,43).
Muslim immigrants in Denmark are now recommended through
information leaflets to take 10mg vitamin D supplements/d.
The present study on one hand clearly demonstrates that the
vitamin D status of severely vitamin D-deficient Pakistani
immigrants in Denmark increases two to four times with
relatively small dosages of supplemental vitamin D, and that
S-iPTH decreases at the same time. On the other hand, this
improvement in vitamin D and PTH status did not benefit
bone mass and bone turnover parameters. The optimal vitamin
D nutrition for skeletal health in different ethnic groups should
be further investigated.
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